Table 3.
Methylation Status of p16, MINT2, or MINT31 in 108 Adenomas Compared to Patient and Adenoma Characteristics
| Characteristic | Total (no.) | Unmethylated, all loci assayed (n = 56) % (no.) | Methylated, any locus (n = 52) % (no.) |
|---|---|---|---|
| Age (years)± SD | 63 ± 12 | 64 ± 11 | 62 ± 13 |
| Sex | |||
| Female | 40 | 50 (20) | 50 (20) |
| Male | 68 | 53 (36) | 47 (32) |
| Site | |||
| Right | 47 | 55 (26) | 45 (21) |
| Left | 59 | 49 (29) | 51 (30) |
| Not designated | 2 | 50 (1) | 50 (1) |
| Size in cm± SD | 0.74 ± 0.79 | 0.56 ± 0.42 | 0.92 ± 1.02 |
| Histopathology | |||
| Tubular | 85 | 59 (50) | 41 (35) |
| Tubulovillous/villous | 23 | 26 (6) | 73 (17) |
| Other genetic alterations | |||
| K-ras | 43 | 58 (25) | 41 (18) |
| p53 overexpression | 9 | 44 (4) | 56 (5) |
| MSI-high* | 7 | 85 (6) | 15 (1) |
| 18q loss* | 3 | 33 (1) | 67 (2) |
*Microsatellite instability and 18q loss was not assessed for nine adenomas without methylation and six adenomas with methylation.